Marta Bonora - Academia.edu (original) (raw)

Papers by Marta Bonora

Research paper thumbnail of Left ventricular assist devices promote changes in the expression levels of platelet microRNAs

Frontiers in Cardiovascular Medicine

IntroductionMicroRNAs (miRs) emerged as promising diagnostic and therapeutic biomarkers in cardio... more IntroductionMicroRNAs (miRs) emerged as promising diagnostic and therapeutic biomarkers in cardiovascular diseases. The potential clinical utility of platelet miRs in the setting of left ventricular assist device (LVAD) support is unexplored.MethodsWe prospectively measured the expression levels of 12 platelet miRs involved in platelet activation, coagulation, and cardiovascular diseases in LVAD patients by quantitative real-time polymerase chain reaction. Data were longitudinally measured before LVAD implant and after 1, 6, and 12 months of LVAD support, and compared with those measured in healthy volunteers (controls). In silico analysis was also performed to identify pathways targeted by differentially expressed miRs.ResultsData from 15 consecutive patients and 5 controls were analyzed. Pre-implant expression levels of platelet miR-126, miR-374b, miR-223, and miR-320a were significantly different in patients vs. controls. The expression levels of platelet miR-25, miR-144, miR-320...

Research paper thumbnail of Design and Manufacturing of Microtextured Patient-Specific Coronary Stent

Proceedings of the 16th International Joint Conference on Biomedical Engineering Systems and Technologies, 2023

Research paper thumbnail of Analysis of platelet-derived microparticles and their role in platelet activation and stimulation under static and dynamic conditions

We would like to acknowledge our supervisors Professor, Alberto Redaelli, for giving us the possi... more We would like to acknowledge our supervisors Professor, Alberto Redaelli, for giving us the possibility to work on this project and Professor Marvin J. Slepian for welcoming us as part of the team. We also would like to thank Silvia Bozzi, PhD, for the support and technical advices she gave us during the work. We would also like to acknowledge the Sarver Heart Centre team, Daniel, Sparky, Allegra, Kaitlyn, Adriana, Yana and Sam for their help and their friendship. A special acknowledgment goes to our families for the opportunity they gave us to follow our dreams and for supporting us during this experience. A kindly thought goes to all our friends, for the lovely time we've spent together and all their support. Finally, we would like to thank each other for supporting, affection, patience and understanding.

Research paper thumbnail of Platelet activation state in early stages of COVID-19

Minerva Anestesiologica, 2022

BACKGROUND Platelet activation at the early stage of COVID-19 is poorly described. The need for a... more BACKGROUND Platelet activation at the early stage of COVID-19 is poorly described. The need for antiplatelet therapy in patients with COVID-19 remains controversial. We characterized the platelet activation profile in hospitalized patients at the early stage of COVID-19 using the modified prothrombinase Platelet Activation State (PAS) assay. METHODS Sixteen patients admitted to the emergency department of the IRCCS San Raffaele Scientific Institute (Milano, Italy) between February 8 and April 2021 were enrolled. All patients presented with respiratory symptoms and tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Platelet activation was measured via the PAS assay within 24 hours from patients' hospital admission. Data were compared with those measured in n=24 healthy subjects (controls). RESULTS Platelet activation was significantly higher in COVID-19 patients with respect to controls (PAS = 0.63 [0.58-0.98]% vs. 0.46 [0.40-0.65]%, respectively; p=0.03). Of note, highest PAS values were measured in the two patients with the worst clinical outcome, i.e., death because of respiratory failure (PAS = 2.09% and 1.20%, respectively). No differences in standard coagulation parameters were noted between these two patients and those who were later discharged home. CONCLUSIONS This study provides evidences of significant platelet activation state at the early stage of COVID-19 and suggests that the patient-specific platelet activation profile is a reliable clinical marker to stratify COVID-19 patients at high risk of poor clinical outcome who might potentially benefit from antiplatelet therapy.

Research paper thumbnail of Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics?

European Journal of Cardio-Thoracic Surgery, 2021

OBJECTIVES To evaluate the competing pro-haemorrhagic contribution of acquired von Willebrand (vW... more OBJECTIVES To evaluate the competing pro-haemorrhagic contribution of acquired von Willebrand (vW) disease and antithrombotic therapy in patients implanted with continuous-flow left ventricular assist devices (LVADs). METHODS We compared the extent of vW factor (vWf) degradation [vWf antigen (vWf:Ag)] and a decrease of functional activity of large vWf multimers [vWf collagen binding (vWf:CB)] in LVAD patients who did and did not suffer from bleeding. Data were measured pre-implant, at short-term (t1: <3 months) and long-term (t2: >12 months) follow-up. The occurrence of primary bleeding events, as well as bleeding recurrence, was correlated with patient-specific vWf profile and antithrombotic regimen. Indeed, patients were discharged on warfarin (international normalized ratio: 2–2.5) and aspirin, with the latter withhold after a first bleeding episode. RESULTS Fifty-three patients were enrolled. The median follow-up was 324 (226–468) days. We recorded 25 primary bleeding even...

Research paper thumbnail of Left ventricular assist devices promote changes in the expression levels of platelet microRNAs

Frontiers in Cardiovascular Medicine

IntroductionMicroRNAs (miRs) emerged as promising diagnostic and therapeutic biomarkers in cardio... more IntroductionMicroRNAs (miRs) emerged as promising diagnostic and therapeutic biomarkers in cardiovascular diseases. The potential clinical utility of platelet miRs in the setting of left ventricular assist device (LVAD) support is unexplored.MethodsWe prospectively measured the expression levels of 12 platelet miRs involved in platelet activation, coagulation, and cardiovascular diseases in LVAD patients by quantitative real-time polymerase chain reaction. Data were longitudinally measured before LVAD implant and after 1, 6, and 12 months of LVAD support, and compared with those measured in healthy volunteers (controls). In silico analysis was also performed to identify pathways targeted by differentially expressed miRs.ResultsData from 15 consecutive patients and 5 controls were analyzed. Pre-implant expression levels of platelet miR-126, miR-374b, miR-223, and miR-320a were significantly different in patients vs. controls. The expression levels of platelet miR-25, miR-144, miR-320...

Research paper thumbnail of Design and Manufacturing of Microtextured Patient-Specific Coronary Stent

Proceedings of the 16th International Joint Conference on Biomedical Engineering Systems and Technologies, 2023

Research paper thumbnail of Analysis of platelet-derived microparticles and their role in platelet activation and stimulation under static and dynamic conditions

We would like to acknowledge our supervisors Professor, Alberto Redaelli, for giving us the possi... more We would like to acknowledge our supervisors Professor, Alberto Redaelli, for giving us the possibility to work on this project and Professor Marvin J. Slepian for welcoming us as part of the team. We also would like to thank Silvia Bozzi, PhD, for the support and technical advices she gave us during the work. We would also like to acknowledge the Sarver Heart Centre team, Daniel, Sparky, Allegra, Kaitlyn, Adriana, Yana and Sam for their help and their friendship. A special acknowledgment goes to our families for the opportunity they gave us to follow our dreams and for supporting us during this experience. A kindly thought goes to all our friends, for the lovely time we've spent together and all their support. Finally, we would like to thank each other for supporting, affection, patience and understanding.

Research paper thumbnail of Platelet activation state in early stages of COVID-19

Minerva Anestesiologica, 2022

BACKGROUND Platelet activation at the early stage of COVID-19 is poorly described. The need for a... more BACKGROUND Platelet activation at the early stage of COVID-19 is poorly described. The need for antiplatelet therapy in patients with COVID-19 remains controversial. We characterized the platelet activation profile in hospitalized patients at the early stage of COVID-19 using the modified prothrombinase Platelet Activation State (PAS) assay. METHODS Sixteen patients admitted to the emergency department of the IRCCS San Raffaele Scientific Institute (Milano, Italy) between February 8 and April 2021 were enrolled. All patients presented with respiratory symptoms and tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Platelet activation was measured via the PAS assay within 24 hours from patients' hospital admission. Data were compared with those measured in n=24 healthy subjects (controls). RESULTS Platelet activation was significantly higher in COVID-19 patients with respect to controls (PAS = 0.63 [0.58-0.98]% vs. 0.46 [0.40-0.65]%, respectively; p=0.03). Of note, highest PAS values were measured in the two patients with the worst clinical outcome, i.e., death because of respiratory failure (PAS = 2.09% and 1.20%, respectively). No differences in standard coagulation parameters were noted between these two patients and those who were later discharged home. CONCLUSIONS This study provides evidences of significant platelet activation state at the early stage of COVID-19 and suggests that the patient-specific platelet activation profile is a reliable clinical marker to stratify COVID-19 patients at high risk of poor clinical outcome who might potentially benefit from antiplatelet therapy.

Research paper thumbnail of Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics?

European Journal of Cardio-Thoracic Surgery, 2021

OBJECTIVES To evaluate the competing pro-haemorrhagic contribution of acquired von Willebrand (vW... more OBJECTIVES To evaluate the competing pro-haemorrhagic contribution of acquired von Willebrand (vW) disease and antithrombotic therapy in patients implanted with continuous-flow left ventricular assist devices (LVADs). METHODS We compared the extent of vW factor (vWf) degradation [vWf antigen (vWf:Ag)] and a decrease of functional activity of large vWf multimers [vWf collagen binding (vWf:CB)] in LVAD patients who did and did not suffer from bleeding. Data were measured pre-implant, at short-term (t1: <3 months) and long-term (t2: >12 months) follow-up. The occurrence of primary bleeding events, as well as bleeding recurrence, was correlated with patient-specific vWf profile and antithrombotic regimen. Indeed, patients were discharged on warfarin (international normalized ratio: 2–2.5) and aspirin, with the latter withhold after a first bleeding episode. RESULTS Fifty-three patients were enrolled. The median follow-up was 324 (226–468) days. We recorded 25 primary bleeding even...